Belzutifan

Brand names: Welireg · Active ingredient: Belzutifan

In short: WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. WELIREG, in combinatio

Forms & strengthsTablets: 40 mg, blue, oval shaped, film-coated, debossed with “177” on one side and plain on the other side.
LabelMerck Sharp & Dohme LLC
Label updatedOct 12, 2026

What is Belzutifan used for?

WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

WELIREG, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

WELIREG, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

WELIREG, as monotherapy, is indicated for the treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

⚠ Boxed warning (FDA's strongest warning)

Exposure to WELIREG during pregnancy can cause embryo-fetal harm.

Verify pregnancy status prior to the initiation of WELIREG.

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective [see Warnings and Precautions (5.4), Drug Interactions (7.2), Use in Specific Populations (8.1, 8.3)].

Belzutifan dosage

The recommended dosages for WELIREG are listed in Table 1.

Indication | Recommended WELIREG Dosage | Duration of Therapy

von Hippel-Lindau Disease | 120 mg orally once daily. | Until disease progression or unacceptable toxicity.

Adjuvant Treatment of ccRCC | 120 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph.Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for dosing and administration information. | Until disease recurrence or unacceptable toxicity, or up to 54 weeks.

Advanced ccRCC | 120 mg orally once daily as monotherapy or in combination with lenvatinib. | Until disease progression or unacceptable toxicity.

Pheochromocytoma or Paraganglioma | Adults:

120 mg orally once daily.

Pediatric patients 12 years and older based on bodyweight:

Patients weighing 40 kg or greater: 120 mg orally once daily.

Patients weighing less than 40 kg: 80 mg orally once daily. | Until disease progression or unacceptable toxicity.

Administration Instructions

WELIREG should be taken at the same time each day and may be taken with or without food .

Advise patients to swallow tablets whole. Do not chew, crush, or split WELIREG prior to swallowing.

If a dose of WELIREG is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for WELIREG the next day. Do not take extra tablets to make up for the missed dose.

If vomiting occurs any time after taking WELIREG, do not retake the dose. Take the next dose on the next day.

Dosage modifications for WELIREG for adverse reactions are summarized in Table 2 and Table 3.

The recommended dose reductions are:

First dose reduction: WELIREG 80 mg orally once daily

Second dose reduction: WELIREG 40 mg orally once daily

Third dose reduction: Permanently discontinue

Adverse Reaction | Severity | Dosage Modification

Anemia

| Adjuvant ccRCC Indication:

Hemoglobin <9 g/dL or transfusion indicated | Withhold WELIREG until hemoglobin ≥9 g/dL.

Resume WELIREG at the same or reduced dose; or discontinue depending on the severity of anemia.

Life-threatening or urgent intervention indicated | Withhold WELIREG until hemoglobin ≥9 g/dL.

Resume WELIREG at a reduced dose once resolved, or permanently discontinue.

All Other Indications:

Hemoglobin <8 g/dL or transfusion indicated | Withhold WELIREG until hemoglobin ≥8 g/dL.

Resume WELIREG at the same or reduced dose; or discontinue depending on the severity of anemia.

Life-threatening or urgent intervention indicated | Withhold WELIREG until hemoglobin ≥8 g/dL.

Resume WELIREG at a reduced dose once resolved, or permanently discontinue. …

How to take Belzutifan — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Anemia

Inform patients that WELIREG can cause severe anemia that may require blood transfusions and that red blood cell levels will be monitored routinely during treatment. Advise patients to contact their healthcare provider if the patient experiences any symptoms suggestive of anemia .

Hypoxia

Inform patients that WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization; and that oxygen levels will be monitored routinely during treatment. Advise patients to contact their healthcare provider if the patient experiences any symptoms suggestive of hypoxia .

Cardiac Dysfunction

Inform patients that WELIREG in combination with lenvatinib can cause cardiac dysfunction. Advise patients to immediately contact their healthcare provider for any symptoms or signs of cardiac dysfunction .

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy . …

Warnings & precautions

Do not take this medicine if: None.

WELIREG can cause severe anemia that can require blood transfusion.

Monitor for anemia before initiation of, and periodically throughout, treatment with WELIREG. Transfuse patients as clinically indicated. Withhold, reduce dose, or permanently discontinue WELIREG based on severity .

von Hippel-Lindau (VHL) disease

In LITESPARK-004, decreased hemoglobin occurred in 93% of patients and 7% had Grade 3 events . Median time to onset of anemia was 31 days (range: 1 day to 8.4 months).

The safety of erythropoiesis stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG has not been established. Randomized controlled trials in patients with cancer receiving myelosuppressive chemotherapy with ESAs have shown that ESAs increased the risks of death and serious cardiovascular reactions, and decreased progression-free survival and/or overall survival. See the prescribing information for ESAs for more information.

Renal Cell Carcinoma with a Clear Cell Component (ccRCC)

In LITESPARK-005, decreased hemoglobin occurred in 88% of patients and 29% had Grade 3 events . Median time to onset of anemia was 29 days (range: 1 day to 16.6 months). Of the patients with anemia, 22% received transfusions only, 20% of patients received ESAs only and 12% received both transfusion and ESAs.

In LITESPARK-022, decreased hemoglobin occurred in 95% of patients receiving WELIREG in combination with pembrolizumab and 11% had Grade 3 or higher events . Median time to onset of anemia was 42 days (range: 1 day to 11.1 months). Of the patients with anemia, 5% received transfusions only, 8% received ESAs only, and 1.3% received both transfusion and ESAs.

In LITESPARK-011, decreased hemoglobin occurred in 87% of patients receiving WELIREG in combination with lenvatinib and 20% had Grade 3 events or required transfusion . …

Belzutifan side effects

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

Anemia

Hypoxia

Cardiac Dysfunction with Concomitant Use of WELIREG and Lenvatinib

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

von Hippel-Lindau (VHL) disease

LITESPARK-004

The safety of WELIREG was evaluated in an open-label clinical trial (LITESPARK-004) in 61 patients with VHL disease who had at least one measurable solid tumor localized to the kidney . Patients received WELIREG 120 mg orally once daily until disease progression or unacceptable toxicity. The median duration of exposure to WELIREG was 68 weeks (range: 8.4 to 104.7 weeks).

Serious adverse reactions occurred in 15% of patients who received WELIREG, including anemia, hypoxia, anaphylaxis reaction, retinal detachment, and central retinal vein occlusion (1 patient each).

Permanent discontinuation of WELIREG due to adverse reactions occurred in 3.3% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG were dizziness and opioid overdose (1.6% each).

Dosage interruptions of WELIREG due to an adverse reaction occurred in 39% of patients. …

Drug interactions

UGT2B17 or CYP2C19 Inhibitors

Monitor for anemia and hypoxia and reduce the dosage of WELIREG as recommended [see

Dosage and Administration (2.2), Warnings and Precautions (5.1, 5.2), Adverse Reactions (6)].

Coadministration of WELIREG with inhibitors of UGT2B17 or CYP2C19 increases belzutifan exposure , which may increase the risk of adverse reactions of WELIREG.

CYP3A4 Substrates

Avoid coadministration of WELIREG with sensitive CYP3A4 substrates, for which minimal decrease in concentration may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information.

Coadministration of WELIREG with CYP3A4 substrates decreases concentrations of CYP3A substrates , which may reduce the efficacy of these substrates. The magnitude of this decrease may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolizers .

Hormonal Contraceptives

Coadministration of WELIREG with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding .

About this medicine

Belzutifan is an inhibitor of hypoxia-inducible factor-2α (HIF-2α). The chemical name of belzutifan is 3-[[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluorobenzonitrile. The molecular formula is C17H12F3NO4S and the molecular weight is 383.34 Daltons. The chemical structure is:

Belzutifan is a white to light brown powder that is soluble in acetonitrile, dimethoxyethane, and acetone, sparingly soluble in ethyl acetate, very slightly soluble in isopropanol and toluene, and insoluble in water.

WELIREG is supplied as blue, film-coated tablets for oral use containing 40 mg of belzutifan together with croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide, as inactive ingredients. In addition, the film-coating contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.

How it works: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 13e15ee0-d679-4fa9-9430-e2e2170474da. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate